Completed PHASE2 INTERVENTIONAL NCT00219791

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage

Sponsor: BTG International Inc.

Conditions Neoplasms

Interventions glucarpidase (50 Units/kg)

Updated 5 times since 2017 Last updated: Sep 10, 2014 Started: Jan 31, 2000 Completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00219791, this PHASE2 trial focuses on Neoplasms and remains completed. Sponsored by BTG International Inc., it has been updated 5 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BTG International Inc.

Data source: BTG International Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany